A Study Testing the Effect of Immunotherapy (Ipilimumab and Nivolumab) in Patients With Recurrent Glioma With Elevated Mutational Burden

Clinical trial NCT04145115 · ACTIVE_NOT_RECRUITING

Trial details

NCT number: NCT04145115
Sponsor: National Cancer Institute (NCI)
Status: ACTIVE_NOT_RECRUITING
Phase: Phase 2
Study type: INTERVENTIONAL

Astrocytoma, IDH-Mutant, Grade 4 Diffuse Glioma Glioblastoma, IDH-Wildtype Secondary Glioblastoma

Start date: 2020-12-24
Primary completion: 2026-12-31
Enrollment: 37

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.